XNAS · AVBP
+0.00% · +$0.0000 · Vol Not reported
Market closed · last close shown
ArriVent BioPharma, Inc. Common Stock

ArriVent BioPharma, Inc. Common Stock

PHARMACEUTICAL PREPARATIONS
$29.12
Card
Relationship Map

Veridion Score

BETALOW CONF · 5/6 factorsMethodology
Sentiment absence reason unknown
AVBP
ArriVent BioPharma, Inc. Common Stock
Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

59/ 100
Veridion Score
NEUTRAL · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 5/6 factors with data · Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is AVBP moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading AVBP catalysts
About ArriVent BioPharma, Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Listed since
2024
Employees
77
Country
US

ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$29.12
Last session
Day high
$29.12
Last session
Day low
$29.12
Last session
Previous close
$29.12
52W high
$34.74
-16.18% from high
52W low
$17.17
68% of range
Market cap
$1.4B
EPS
$-3.7400
Beta
0.64
Shares out
49.3M
Avg volume
462.3K
VWAP
$29.12
Last session
Price history computed in-house
1W
+0.38%
1M
-8.23%
3M
+4.22%
1Y
+44.80%
YTD
+44.73%
SMA 50 $31.57 · below
SMA 200 $26.16 · above
52W position 68%

AVBP overview

Veridion Score
59
Registered · 2026-08-21
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around AVBP.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading AVBP Form 4 filings
Public disclosures

Congress activity in AVBP

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for AVBP in the cached public ledger.

Federal contracts

AVBP contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for AVBP in this window.
Lobbying spend

AVBP lobbying filings, year to date.

Registered lobbying filings matched to ArriVent BioPharma, Inc. Common Stock.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for AVBP in this window.
Loading news for AVBP
Analyst ratings
Sovereign unlock shows live analyst consensus for AVBP.
Options
Sovereign unlock shows live options positioning for AVBP.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.